Name: Tenofovir
Brand: Selleck Chemicals
SKU: S1401
Availability: InStock
Rating: 5 (28 reviews)

Jump to

Quality Control

Batch: Purity: 99.98%

99.98

Related Targets	Integrase Bacterial Antibiotics Anti-infection Fungal Antiviral COVID-19 Parasite HIV HCV Protease
Other Reverse Transcriptase Products	Dapivirine (TMC120) Salicylanilide Fangchinoline Bifendate 3'-Fluoro-3'-deoxythymidine (Alovudine) Ulonivirine Lersivirine (UK-453061) 4-Chloro-2-(trifluoroacetyl)aniline hydrochloride

Cell Culture, Treatment & Working Concentration

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description
human MT2 cells	Function assay		5 days	Antiviral activity against HIV1 3B infected in human MT2 cells assessed as inhibition of virus-induced cytopathic effect after 5 days by XTT assay, EC50=0.013 μM
human H9 cells	Function assay			Antiviral activity against HIV1 clade F isolate 2338 infected in human H9 cells assessed as inhibition of viral replication, EC50=0.04 μM
C3H/3T3 cells	Function assay		6 days	Inhibition of murine sarcoma virus-induced transformation of mouse embryo fibroblast C3H/3T3 cells after 6 days, EC50=0.23 μM
CEM (human leukemia) cells	Function assay			Antiviral activity against HIV-1 (IIIB) in CEM (human leukemia) cells, EC50=1.2 μM
MT-4 cells	Function assay			In vitro antiviral activity against HIV-2 in MT-4 cells, EC50=1.4 μM
human bone marrow cells	Cytotoxicity assay		24 h	Cytotoxicity against human bone marrow cells after 24 hrs by BFU-E assay, CC50=3.5 μM
C8166 cells	Function assay		4 days	Antiviral activity against 100 TCID50 wild-type Human immunodeficiency virus type 2 ROD infected in C8166 cells assessed as inhibition of syncytia formation after 4 days by microscopic analysis, EC50=7.1 μM
mouse L1210 cells	Cytotoxicity assay		48 h	Cytostatic activity against mouse L1210 cells after 48 hrs by coulter counting analysis, IC50=11 μM
human HepG2 cells	Function assay		9 days	Antiviral activity against Hepatitis B virus infected human HepG2 cells after 9 days by MTT assay, IC50=12.3 μM
human HeLa cells	Cytotoxicity assay		72 h	Cytostatic activity against human HeLa cells after 72 hrs by coulter counting analysis, IC50=17 μM
CHO cells	Cytotoxicity assay		120 h	Cytotoxicity against CHO cells after 120 hrs by Cell-Titer Glo assay, CC50=21 μM
MDCK2 cells	Function assay	10 μM		Inhibition of human MRP3 expressed in MDCK2 cells assessed as increase in intracellular CMF fluorescence at 10 uM by CMFDA assay
human HepG2 cells	Cytotoxicity assay		14 days	Cytotoxicity against human HepG2 cells assessed as inhibition of cellular DNA replication after 14 days
Click to View More Cell Line Experimental Data

Solubility

In vitro
Batch:

DMSO : 4 mg/mL (13.92 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Water : 2 mg/mL

Ethanol : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	30%propylene glycol 1 5%Tween80 2 65%D5W Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	30.000mg/ml (104.45mM)	Taking the 1 mL working solution as an example, add 300 μL of 100 mg/ml clarified propylene glycol stock solution to 50 μL of Tween 80, mix evenly to clarify it; then continue to add 650 μL of D5W to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	287.21	Formula	C₉H₁₄N₅O₄P	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	147127-20-6	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	GS-1278			Smiles	CC(CN1C=NC2=C(N=CN=C21)N)OCP(=O)(O)O

Mechanism of Action

Features	Tenofovir disoproxil fumarate is the prodrug form of tenofovir.
Targets/IC₅₀/Ki	Reverse transcriptase
In vitro	Tenofovir reduces the viral cytopathic effect of HIV-1(IIIB), HIV-2(ROD) and HIV(EHO) with EC50 of 1.15 μg/mL, 1.12 μg/mL and 1.05 μg/mL in MT-4 cells. This compound also reduces the viral cytopathic effect of SIV(mac251) , SIV(B670) ,SHIV(89.6) and SHIV(RTSHIV). It is uniquely active against multinucleoside-resistant HIV expressing the Q151M mutation, but shows reduced susceptibility to the T69S insertion mutations. This chemical inhibits hepatitis B virus (HBV) activity in HepG2 2.2.15, HepAD38 and HepAD79 cells. It (4 μM) completely inhibits the growth of HIVIIIB in MT-2 cells. This compound inhibits synthesis of negative strand strong-stop DNA with IC50 of 9 µM for wild-type RT, 6 µM for M184V RT and 50 µM for K65R RT.
In vivo	Tenofovir (30 mg/kg) completely prevents SIV infection in all macaques without toxicity. This compound reduces plasma viral RNA levels to undetectable, with parallel decreases in the infectivity of plasma and infectious cells in peripheral blood mononuclear cells and cerebrospinal fluid (CSF) and stabilization of CD4+ T-cell numbers. It completely abrogates HIV infection via intravaginal exposure in pig-tailed macaques.
References	[1] https://pubmed.ncbi.nlm.nih.gov/15040537/ [2] https://pubmed.ncbi.nlm.nih.gov/11562951/ [3] https://pubmed.ncbi.nlm.nih.gov/10760047/ [4] https://pubmed.ncbi.nlm.nih.gov/10682153/ [5] https://pubmed.ncbi.nlm.nih.gov/14557287/

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Tenofovir Reverse Transcriptase inhibitor

Chemical Structure

Molecular Weight: 287.21